GSK Pays $90M To Settle States' Claims Over Avandia Risks
By Daniel Wilson (November 15, 2012, 2:30 PM EST) -- GlaxoSmithKline PLC has agreed to pay $90 million to settle the claims of 37 states and the District of Columbia that it had unlawfully misrepresented the cardiovascular-related risks of diabetes treatment Avandia, several state attorneys general announced Thursday.
The settlement resolves claims that the pharmaceutical giant had unfairly and deceptively represented Avandia as lowering cholesterol without evidence, and as having cardiovascular benefits when it may have actually increased cardiovascular risks. The company has not admitted to any wrongdoing or liability under the various states' consumer laws.
Arizona Attorney General Tom Horne said in a statement Thursday that the settlement was a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!